{
    "clinical_study": {
        "@rank": "100813", 
        "acronym": "HNO-2", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m\u00b2), cisplatin (75mg/m\u00b2) and 5-fluorouracil (750mg/m\u00b2) followed by Cetuximab (weekly, starting with 400mg/m\u00b2 then continuing with 250 mg/m\u00b2) with radiotherapy (concomitant boost for 6 weeks).\nActive comparator is 5-fluorouracil for first three cycles."
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Experimental", 
                "description": "All patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m\u00b2), cisplatin (75mg/m\u00b2) Cetuximab (weekly, starting with 400mg/m\u00b2 and continuing with 250 mg/m\u00b2), followed by Cetuximab (weekly 250 mg/m\u00b2) with radiotherapy (concomitant boost for 6 weeks).\nExperimental: cetuximab for the first three cycles."
            }
        ], 
        "brief_summary": {
            "textblock": "This multicentre, randomised Phase II Pilot Study evaluates the efficacy of docetaxel,\n      cisplatin and 5-fluorouracil or Cetuximab, followed by Cetuximab with radiotherapy."
        }, 
        "brief_title": "Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Squamous Cell Carcinoma of the Hypopharynx Stage III", 
            "Squamous Cell Carcinoma of the Hypopharynx Stage IV", 
            "Squamous Cell Carcinoma of the Larynx Stage III", 
            "Squamous Cell Carcinoma of the Larynx Stage IV", 
            "Squamous Cell Carcinoma of the Oropharynx Stage III", 
            "Squamous Cell Carcinoma of the Oropharynx Stage IV", 
            "Squamous Cell Carcinoma of the Oral Cavity Stage III", 
            "Squamous Cell Carcinoma of the Oral Cavity Stage IV"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Laryngeal Diseases", 
                "Hypopharyngeal Neoplasms", 
                "Laryngeal Neoplasms", 
                "Oropharyngeal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "It will be evaluated whether 5-FU can be replaced by immunotherapy with cetuximab within a\n      taxane/cisplatin-containing induction-chemotherapy scheme for advanced carcinoma of the head\n      and neck. As 5-FU causes severe mucosal toxicities which are added to known toxicities of\n      cisplatin, a combination-therapy with reduced toxicities and same efficacy would be a\n      acceptable alternative to patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed local advanced squamous cell carcinoma of the Larynx,\n             Hypopharynx, Oropharynx or Cavum oris stage III and IV\n\n          -  One measureable lesion (CT oder MR)\n\n          -  Age 18 - 75 (including)\n\n          -  Performance Score ECOG 0 - 1\n\n        Exclusion Criteria selected:\n\n          -  Distant metastases\n\n          -  ECOG Score >1\n\n          -  Prior radiation (Head and neck area)\n\n          -  Creatinin Clearance below 60 ml/\u00b5l\n\n          -  Acute infections\n\n          -  Neuropathy grade 3 or 4\n\n          -  Myocardial Infarction within the last 12 months\n\n          -  Acute coronary syndrome or othe clinically significant cardiovascular diseases"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01884259", 
            "org_study_id": "AGMT_HNO 2"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "A", 
                    "B"
                ], 
                "description": "75 mg/m\u00b2 on day 1 of 21-days cycle", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "A", 
                    "B"
                ], 
                "description": "75 mg/m\u00b2 on day 1 of 21-days cycle", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "A", 
                "description": "750 mg/m\u00b2 day 1 to 5 during 24 hours of 21-days cycle", 
                "intervention_name": "5-fluorouracil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B", 
                "description": "weekly, starting with 400 mg/m\u00b2 during 120 min.(saturation) then continuing with 250 mg/m\u00b2; duration 3 cycles with 21 days", 
                "intervention_name": "Cetuximab Induction", 
                "intervention_type": "Biological", 
                "other_name": "Erbitux"
            }, 
            {
                "arm_group_label": [
                    "A", 
                    "B"
                ], 
                "description": "weekly, starting with 400 mg/m\u00b2 during 120 min.(saturation only arm A) then continuing with 250 mg/m\u00b2; duration 7 weeks", 
                "intervention_name": "Cetuximab Radioimmunotherapy", 
                "intervention_type": "Biological", 
                "other_name": "Erbitux"
            }, 
            {
                "arm_group_label": [
                    "A", 
                    "B"
                ], 
                "description": "First 18 irradiations once daily with single dose of 1,8 Gy for 5 days per week. In addition by day 19 a second irradiation boost will be applied for further 12 days(1,5 Gy per day with at least 5 hours interval to 1,8 Gy dose. This results in total clinical target dose of 72 Gy and total subclinical target dose of 54 Gy. Duration of irradiation: 6 weeks", 
                "intervention_name": "Boost irradiation", 
                "intervention_type": "Radiation", 
                "other_name": "Concomitant boost-irradiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Cetuximab", 
                "Cisplatin", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "local advanced squamous cell carcinoma", 
            "Larynx", 
            "Hypopharynx", 
            "Oropharynx", 
            "Cavum oris", 
            "docetaxel", 
            "cisplatin", 
            "5-fluorouracil", 
            "Cetuximab"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "link": {
            "description": "Sponsor", 
            "url": "http://www.agmt.at"
        }, 
        "location": [
            {
                "contact": {
                    "email": "alexander.devries@lkhf.at", 
                    "last_name": "Alexander DeVries, Prof.Dr.", 
                    "phone": "+43 5522 303", 
                    "phone_ext": "3300"
                }, 
                "facility": {
                    "address": {
                        "city": "Feldkirch", 
                        "country": "Austria", 
                        "zip": "A-6807"
                    }, 
                    "name": "Landeskrankenhaus Feldkirch"
                }, 
                "investigator": {
                    "last_name": "Alexander DeVries, Prof.Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "office@osteoprotect.at", 
                    "last_name": "Gabi Schmoranzer", 
                    "phone": "+43 6769101268"
                }, 
                "contact_backup": {
                    "email": "office3@osteoprotect.at", 
                    "last_name": "Elisabeth Zwickl-Traxler, MSc"
                }, 
                "facility": {
                    "address": {
                        "city": "Krems", 
                        "country": "Austria", 
                        "zip": "A-3500"
                    }, 
                    "name": "Landesklinikum Krems"
                }, 
                "investigator": {
                    "last_name": "Martin Pecherstorfer, Prof.Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "magdalena.sturm@bhs.at", 
                    "last_name": "Magdalena Sturm, DI", 
                    "phone": "+43 732 7677", 
                    "phone_ext": "7521"
                }, 
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "zip": "A-4010"
                    }, 
                    "name": "Krankenhaus d. Barmherzigen Schwestern Linz"
                }, 
                "investigator": {
                    "last_name": "Martin Burian, Prof.Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bettina.pfleger@akh.linz.at", 
                    "last_name": "Bettina Pfleger", 
                    "phone": "+43 7327806", 
                    "phone_ext": "6207"
                }, 
                "contact_backup": {
                    "email": "elisabeth.morbitzer@akh.linz.at", 
                    "last_name": "Elisabeth Morbitzer", 
                    "phone": "+43 7327806", 
                    "phone_ext": "6204"
                }, 
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "zip": "A-4021"
                    }, 
                    "name": "AKH Linz, Innere Medizin 3, Zentrum f. Haematologie u. med. Onkologie"
                }, 
                "investigator": {
                    "last_name": "Michael A. Fridrik, Univ.Doz.Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "m.schachner@salk.at", 
                    "last_name": "Michaela Schachner, Mag.", 
                    "phone": "+43 662 4482", 
                    "phone_ext": "2847"
                }, 
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria", 
                        "zip": "5020"
                    }, 
                    "name": "PMU Salzburg"
                }, 
                "investigator": {
                    "last_name": "Richard Greil, Prof. Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "felix.keil@wgkk.at", 
                    "last_name": "Felix Keil, Prof.Dr."
                }, 
                "contact_backup": {
                    "email": "eva.sallaberger@wgkk.at", 
                    "last_name": "Eva Sallaberger, MSc"
                }, 
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "1140"
                    }, 
                    "name": "Hanusch Krankenhaus Wien"
                }, 
                "investigator": {
                    "last_name": "Felix Keil, Prof.Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "edgar.selzer@meduniwien.ac.at", 
                    "last_name": "Edgar Selzer, Prof.Dr.", 
                    "phone": "+43 1 40400", 
                    "phone_ext": "2650"
                }, 
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "A-1090"
                    }, 
                    "name": "Universit\u00e4t f. Strahlentherape, AKH Wien"
                }, 
                "investigator": {
                    "last_name": "Edgar Selzer, Prof.Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ina.puehringer@klinikum-wegr.at", 
                    "last_name": "Ina P\u00fchringer", 
                    "phone": "+43 7242 415", 
                    "phone_ext": "92185"
                }, 
                "contact_backup": {
                    "email": "bettina.buchbauer@klinikum-wegr.at", 
                    "last_name": "Bettina Buchbauer"
                }, 
                "facility": {
                    "address": {
                        "city": "Wels", 
                        "country": "Austria", 
                        "zip": "A-4600"
                    }, 
                    "name": "Klinikum Kreuzschwestern Wels GmbH"
                }, 
                "investigator": {
                    "last_name": "Beate Mayrb\u00e4url, OA Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomised Phase II Pilot Study: Induction Chemotherapy With Docetaxel, Cisplatin and Cetuximab Versus Docetaxel, Cisplatin and 5 FU Followed by Radiotherapy With Cetuximab for Locally Advanced or Not Resectable Carcinoma of the Head and Neck", 
        "overall_official": {
            "affiliation": "Hanuschkrankenhaus", 
            "last_name": "Felix Keil, Prof.Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "RECIST criteria", 
            "measure": "Response Rate (CR, PR)", 
            "safety_issue": "No", 
            "time_frame": "3 months after end of therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01884259"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "RECIST", 
                "measure": "Overall Response Rate (CR, PR, PD, SD)", 
                "safety_issue": "No", 
                "time_frame": "until 3 months after therapy"
            }, 
            {
                "measure": "Locoregionally monitoring", 
                "safety_issue": "No", 
                "time_frame": "after one year"
            }, 
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "1,  2 and 5 years after start of therapy"
            }, 
            {
                "description": "Information about acute toxicity (grade, relation to study drug) during study treatment and until 3 months after end of radiotherapy will be collected for each patient using CTCAE 3.0 criteria list.\nInformation about late toxicity (grade) will be collected after 3 months of radiotherapy and until 60 months after radiotherapy using RTOG/EORTC toxicity criteria.\nKind and number of toxicities will be described according to grade. The highest grade of each patient and toxicity will be analysed.", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "During treatment and until 60 months after end of radiotherapy"
            }, 
            {
                "measure": "Overall-Survival", 
                "safety_issue": "No", 
                "time_frame": "1,  2 and 5 years after start of therapy"
            }
        ], 
        "source": "Arbeitsgemeinschaft medikamentoese Tumortherapie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Arbeitsgemeinschaft medikamentoese Tumortherapie", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}